Pablo Zubiaur, Paula Soria-Chacartegui, Erin C Boone, Bhagwat Prasad, Jean Dinh, Wendy Y Wang, Santiago Zugbi, Andrea Rodríguez-Lopez, Eva González-Iglesias, J Steven Leeder, Francisco Abad-Santos, Andrea Gaedigk
A novel haplotype composed of two non-coding variants, CYP2C18 NM_000772.3:c.*31T (rs2860840) and NM_000772.2:c.819+2182G (rs11188059), referred to as "CYP2C:TG", was recently associated with ultrarapid metabolism of various CYP2C19 substrates. As the underlying mechanism and clinical relevance of this effect remain uncertain, we analyzed existing in vivo and in vitro data to determine the magnitude of the CYP2C:TG haplotype effect. We assessed variability in pharmacokinetics of CYP2C19 substrates, including citalopram, sertraline, voriconazole, omeprazole, pantoprazole and rabeprazole in 222 healthy volunteers receiving one of these six drugs...
August 1, 2023: Clinical Pharmacology and Therapeutics